Roth Capital Reduces Earnings Estimates for Nuvectis Pharma

Key Points

• Roth Capital has lowered its earnings per share estimate for Nuvectis Pharma, projecting a loss of ($0.22) for Q3 2025, down from a previous estimate of ($0.20).
• Nuvectis Pharma recently reported a Q2 earnings loss of ($0.30) per share, missing analysts' expectations by ($0.05).
• Despite declining earnings forecasts, the company has seen significant institutional investment, with over 96% of its shares owned by institutional investors and hedge funds.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities research analysts at Roth Capital decreased their Q3 2025 EPS estimates for shares of Nuvectis Pharma in a research note issued on Tuesday, August 5th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.22) per share for the quarter, down from their previous forecast of ($0.20). The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.39) EPS, FY2028 earnings at $2.43 EPS and FY2029 earnings at $3.37 EPS.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.05).

NVCT has been the subject of several other research reports. Wall Street Zen cut Nuvectis Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, June 29th. HC Wainwright set a $10.00 target price on shares of Nuvectis Pharma and gave the company a "buy" rating in a report on Monday.

Nuvectis Pharma Trading Down 2.8%

NVCT traded down $0.17 on Thursday, hitting $6.00. 177,460 shares of the company were exchanged, compared to its average volume of 226,409. The firm has a 50-day moving average price of $7.90 and a two-hundred day moving average price of $8.24. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $11.80. The company has a market cap of $152.76 million, a price-to-earnings ratio of -5.13 and a beta of -0.26.

Insider Transactions at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri acquired 5,603 shares of the company's stock in a transaction dated Friday, June 20th. The shares were acquired at an average price of $7.99 per share, for a total transaction of $44,767.97. Following the acquisition, the insider owned 2,981,806 shares in the company, valued at $23,824,629.94. The trade was a 0.19% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders bought 60,212 shares of company stock worth $485,964. 30.52% of the stock is owned by insiders.

Hedge Funds Weigh In On Nuvectis Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVCT. Police & Firemen s Retirement System of New Jersey acquired a new stake in Nuvectis Pharma during the second quarter worth approximately $28,000. Cubist Systematic Strategies LLC purchased a new position in shares of Nuvectis Pharma in the 4th quarter valued at $34,000. Blue Zone Wealth Advisors LLC acquired a new stake in Nuvectis Pharma during the 1st quarter worth $102,000. Squarepoint Ops LLC acquired a new stake in Nuvectis Pharma during the 4th quarter worth $103,000. Finally, Northern Trust Corp lifted its position in Nuvectis Pharma by 68.7% in the fourth quarter. Northern Trust Corp now owns 25,725 shares of the company's stock valued at $139,000 after acquiring an additional 10,472 shares during the last quarter. 96.77% of the stock is owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.